Hearing that standard lung cancer treatment is no longer working is one of the hardest moments in a cancer journey. It does not always mean there is nothing left to discuss. Lung cancer care has changed quickly, and the right next step often depends on details such as the type of lung cancer (non-small cell or small cell), its stage, and the results of tumor biomarker testing.
This guide explains the questions worth bringing to your oncologist, when a second opinion can help, and how the FDA’s pre-approval pathways work, so you can have a more informed conversation with your care team.
What to ask your oncologist
Questions specific to lung cancer:
- Has my tumor had comprehensive biomarker (genomic) testing, and should it be repeated now that the cancer has progressed?
- Is my lung cancer non-small cell or small cell, and how does that change the options we should consider?
- Would a new biopsy or liquid biopsy tell us anything that could change the plan?
- Have we considered every approved option for my specific tumor profile?
- Could radiation or another local treatment help control symptoms or specific sites of disease?
Questions worth asking for any advanced cancer:
- What are the goals of treatment from here: control, symptom relief, or comfort?
- Are there any approved options we have not yet discussed, including ones used off-label?
- Would you support me getting a second opinion, and who would you recommend?
- Would a pre-approval pathway such as expanded access or Right to Try be worth discussing for me?
- Can we bring in palliative and supportive care now, alongside any other treatment?
